Home › Compare › ANPCY vs QYLD

ANPCY vs QYLD: Dividend Comparison 2026

ANPCY yields 2985.07% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANPCY wins by $433539968075.09M in total portfolio value
10 years
ANPCY
ANPCY
● Live price
2985.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$433539968075.12M
Annual income
$406,736,225,519,142,500.00
Full ANPCY calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — ANPCY vs QYLD

📍 ANPCY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANPCYQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANPCY + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ANPCY pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANPCY
Annual income on $10K today (after 15% tax)
$253,731.34/yr
After 10yr DRIP, annual income (after tax)
$345,725,791,691,271,200.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, ANPCY beats the other by $345,725,791,691,266,370.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANPCY + QYLD for your $10,000?

ANPCY: 50%QYLD: 50%
100% QYLD50/50100% ANPCY
Portfolio after 10yr
$216769984037.57M
Annual income
$203,368,112,759,574,080.00/yr
Blended yield
93.82%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANPCY buys
0
QYLD buys
0
No recent congressional trades found for ANPCY or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANPCYQYLD
Forward yield2985.07% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$433539968075.12M ✓$25.4K
Annual income after 10y$406,736,225,519,142,500.00 ✓$5,659.31
Total dividends collected$431686299125.80M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ANPCY vs QYLD ($10,000, DRIP)

YearANPCY PortfolioANPCY Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$309,207$298,507.46$10,352$1,192.36+$298.9K → ANPCY
2$8,957,089$8,626,236.93$10,830$1,347.57+$8.95M → ANPCY
3$243,120,454$233,536,368.64$11,460$1,539.07+$243.11M → ANPCY
4$6,184,279,490$5,924,140,604.30$12,275$1,777.84+$6184.27M → ANPCY
5$147,451,722,719$140,834,543,664.57$13,323$2,078.95+$147451.71M → ANPCY
6$3,296,013,356,428$3,138,240,013,119.13$14,667$2,463.34+$3296013.34M → ANPCY
7$69,087,118,460,072$65,560,384,168,694.19$16,396$2,960.57+$69087118.44M → ANPCY
8$1,358,221,282,082,432$1,284,298,065,330,154.50$18,631$3,612.97+$1358221282.06M → ANPCY
9$25,050,226,687,827,436$23,596,929,915,999,230.00$21,548$4,482.15+$25050226687.81M → ANPCY
10$433,539,968,075,117,900$406,736,225,519,142,500.00$25,398$5,659.31+$433539968075.09M → ANPCY

ANPCY vs QYLD: Complete Analysis 2026

ANPCY — Stock

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Full ANPCY Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this ANPCY vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANPCY vs SCHDANPCY vs JEPIANPCY vs OANPCY vs KOANPCY vs MAINANPCY vs XYLDANPCY vs JEPQANPCY vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.